Use of surfactant in neonatal intensive care units
Surfactant is currently an important therapy for newborns in neonatal intensive care units (NICUs) with respiratory problems, specifically respiratory distress syndrome (RDS). Surfactant was initially used in 1959, after it was recognized for maintaining lung inflation at low transpulmonary pressure...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Indonesian Pediatric Society Publishing House
2016-10-01
|
Series: | Paediatrica Indonesiana |
Subjects: | |
Online Access: | https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/879 |
id |
doaj-2f1ea7daa8f24b20814ee91d3f309a4a |
---|---|
record_format |
Article |
spelling |
doaj-2f1ea7daa8f24b20814ee91d3f309a4a2020-11-25T01:29:17ZengIndonesian Pediatric Society Publishing HousePaediatrica Indonesiana0030-93112338-476X2016-10-014562334010.14238/pi45.6.2005.233-40739Use of surfactant in neonatal intensive care unitsM Sholeh KosimSurfactant is currently an important therapy for newborns in neonatal intensive care units (NICUs) with respiratory problems, specifically respiratory distress syndrome (RDS). Surfactant was initially used in 1959, after it was recognized for maintaining lung inflation at low transpulmonary pressures. Avery and Mead in Jobe reported that saline extracts from the lungs of preterm infants with RDS lacked the low surface tension characteristics of pulmonary surfactant. Subsequently, in 1980, clinical potential of surfactant therapy for RDS was demonstrated by Fujiwara et al, reported in Jobe, in the use of surfactant prepared from an organic solvent extracted from bovine lung (Surfactant TA). Small randomized controlled trials (RCTs) in 1985, which tested surfactants prepared from bovine alveolar-lavage or human amniotic fluid, demonstrated significant decrease in pneumothorax and death rates. Subsequent multi-center trials demonstrated decreased death rates and complications of RDS; although still investigational, its use begun in 1989. A synthetic surfactant was approved for the treatment of the syndrome in the United States in 1990, and an animal surfactant was approved in 1991. These surfactants represent a new class of drug developed specifically for preterm infants.https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/879surfactantneonatal intensive care units |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
M Sholeh Kosim |
spellingShingle |
M Sholeh Kosim Use of surfactant in neonatal intensive care units Paediatrica Indonesiana surfactant neonatal intensive care units |
author_facet |
M Sholeh Kosim |
author_sort |
M Sholeh Kosim |
title |
Use of surfactant in neonatal intensive care units |
title_short |
Use of surfactant in neonatal intensive care units |
title_full |
Use of surfactant in neonatal intensive care units |
title_fullStr |
Use of surfactant in neonatal intensive care units |
title_full_unstemmed |
Use of surfactant in neonatal intensive care units |
title_sort |
use of surfactant in neonatal intensive care units |
publisher |
Indonesian Pediatric Society Publishing House |
series |
Paediatrica Indonesiana |
issn |
0030-9311 2338-476X |
publishDate |
2016-10-01 |
description |
Surfactant is currently an important therapy
for newborns in neonatal intensive care units
(NICUs) with respiratory problems,
specifically respiratory distress syndrome
(RDS). Surfactant was initially used in 1959, after it
was recognized for maintaining lung inflation at low
transpulmonary pressures. Avery and Mead in Jobe
reported that saline extracts from the lungs of
preterm infants with RDS lacked the low surface
tension characteristics of pulmonary surfactant.
Subsequently, in 1980, clinical potential of surfactant
therapy for RDS was demonstrated by Fujiwara et al,
reported in Jobe, in the use of surfactant prepared
from an organic solvent extracted from bovine lung
(Surfactant TA). Small randomized controlled trials
(RCTs) in 1985, which tested surfactants prepared
from bovine alveolar-lavage or human amniotic fluid,
demonstrated significant decrease in pneumothorax
and death rates. Subsequent multi-center trials
demonstrated decreased death rates and
complications of RDS; although still investigational,
its use begun in 1989. A synthetic surfactant was
approved for the treatment of the syndrome in the
United States in 1990, and an animal surfactant was
approved in 1991. These surfactants represent a new
class of drug developed specifically for preterm
infants. |
topic |
surfactant neonatal intensive care units |
url |
https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/879 |
work_keys_str_mv |
AT msholehkosim useofsurfactantinneonatalintensivecareunits |
_version_ |
1725097307677917184 |